Company intelligence / Profile preview
Shanghai Argo Biopharmaceutical Co., Ltd.
- Ownership
- Private
- Development stage
- Phase 2
Overview
The company has demonstrated well-tolerated safety profiles across its leading clinical programs. It has completed phase I trials for several siRNA candidates targeting cardiovascular conditions and initiated phase II studies. Its pipeline shows best-in-class potential leveraging the RADS platform to develop next-generation siRNA drugs aiming to reduce dosing frequency significantly.
- Therapeutic areas
- Metabolic DisordersRare DiseasesImmunologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small interfering RNA (siRNA)RNA interference (RNAi) therapeuticsChemical drugs (limited presence)
- Industry
- Biotech
Drug pipeline
26 assets25 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Shanghai Argo Biopharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Argo Biopharmaceutical Co., Ltd..